ReviewInternational journal of molecular sciences2019
Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 114 citations in OpenAlex.
- Downregulation of MGST3 promotes colorectal cancer progression.Molecular and clinical oncology · 2026Article
- Glutathione Redox Activity-An Adaptative Mechanism in Clear Cell Renal Cell Carcinoma.International journal of molecular sciences · 2026Article
- IGF2BP3-dependent glutamine/BCAA metabolic rewiring rejuvenates aged human adipose-derived stem cells for enhanced tissue regeneration.Cell discovery · 2026Article
- Anticancer Potential of Cannabidiol in Renal Cell Carcinoma: Serum Modulation and Preliminary Mechanistic Insights.Journal of clinical medicine · 2026Article
- Beyond angiogenesis: integrating ferroptosis and metabolic rewiring for next-generation RCC therapy.Frontiers in oncology · 2026Review
- Exploration of oxidative stress-related molecular signature for clear cell renal cell carcinoma.Discover oncology · 2025Article
- From Carcinogenesis to Drug Resistance: The Multifaceted Role of Oxidative Stress in Head and Neck Cancer.Cancers · 2025Review
- Lipid reprogramming and ferroptosis crosstalk in clear cell renal cell carcinoma: metabolic vulnerabilities and therapeutic targeting.Molecular cancer · 2025Review
- Identification and experimental validation of mitochondrial and endoplasmic reticulum stress related gene in diabetic nephropathy.Scientific reports · 2025Article
- CENPT prevents renal cell carcinoma against ferroptosis by enhancing the synthesis of glutathione.Cell death & disease · 2025Article
- Pt(IV) Complexes as Anticancer Drugs and Their Relationship with Oxidative Stress.Biomedicines · 2025Review
- Efficient extraction via titanium organic frameworks facilitates in-depth profiling of urinary exosome metabolite fingerprints.Analytical and bioanalytical chemistry · 2025Article
- K-Means Clustering of HyperpolarisedCancers · 2025Article
- CHAC1 in urological tumors: contextual dualism and therapeutic implications.Frontiers in oncology · 2025Review
- HADH suppresses clear cell renal cell carcinoma progression through reduced NRF2-dependent glutathione synthesis.Translational oncology · 2024Article
- TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma.bioRxiv : the preprint server for biology · 2024Article
- Molecular network mechanism in cerebral ischemia-reperfusion rats treated with human urine stem cells.Heliyon · 2024Article
- Gss deficiency causes age-related fertility impairment via ROS-triggered ferroptosis in the testes of mice.Cell death & disease · 2023Article
- Article
- Recent Advances in the Management of Clear Cell Renal Cell Carcinoma: Novel Biomarkers and Targeted Therapies.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A significantly increased level of the reactive oxygen species (ROS) scavenger glutathione (GSH) has been identified as a hallmark of renal cell carcinoma (RCC). The proposed mechanism for increased GSH levels is to counteract damaging ROS to sustain the viability and growth of the malignancy. Here, we review the current knowledge about the three main RCC subtypes, namely clear cell RCC (ccRCC), papillary RCC (pRCC), and chromophobe RCC (chRCC), at the genetic, transcript, protein, and metabolite level and highlight their mutual influence on GSH metabolism. A further discussion addresses the question of how the manipulation of GSH levels can be exploited as a potential treatment strategy for RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.